Table A6.1: Summary of observational studies assessing the use of antivirals

Studies   Design   N   -		Population characteristics	Key results				
Barr 2007	Retrospective cohort study	4,447 received oseltamivir prescription 20,407 did not receive prescription	Children aged 1 to 12 with clinically diagnosed influenza	– Patients prescribed oseltamivir were less likely to develop pneumonia, 0.7% versus 1.4% (RR=0.483; 95% CI: 0.326, 0.717).			
Bowles 2002	Retrospective review	178	Nursing home residents	<ul> <li>Use of oseltamivir within 48 hours of symptom onset resulted in significantly less antibiotic use, fewer hospitalizations and fewer deaths compared to residents receiving no therapy or using amantadine.</li> </ul>			
Blumentals 2007	Retrospective cohort analysis Propensity score matching	36,751 treated with oseltamivir Equal number of matched sample controls	Adolescents ≥13 years and adults diagnosed with seasonal influenza	<ul> <li>Reduction in risk of otitis media of 23% (HR+0.77; 95% CI: 0.65, 0.93).</li> <li>Reduction in any respiratory disease by 18% (HR=0.82; 95% CI: 0.79, 0.86).</li> <li>Reduction in hospitalization for any reason of 22% (HR=0.78; 95% CI: 0.67, 0.91).</li> </ul>			
Casscells 2009	Retrospective review	37,482	Coded history of cardiovascular disease and influenza diagnosis	<ul> <li>Recurrence of CV outcomes within 30 days after influenza diagnosis was significantly lower in treated group (p=0.005).</li> <li>Statistically significant protective effect associated with oseltamivir treatment (OR=0.417; 95% CI: 0.349, 0.498).</li> </ul>			
Cole 2002	Retrospective review of medical /pharmacy health insurance data	2341 treated with zanamivir 2337 untreated comparator group	US patients with diagnosis of seasonal influenza	<ul> <li>Fewer zanamivir-treated patients were hospitalized for complications (RR=0.58; 95% CI: 0.30, 1.12).</li> <li>More outpatient visits for zanamivir-treated patients (16.9% versus 14.5% for untreated patients), RR=1.16; 95% CI: 1.02, 1.33.</li> </ul>			

Studies Design N			Population characteristics	Key results					
Dutkowski 2009	Safety and tolerability study	391	Healthy adults 75mg, 225mg, or 450mg for 5days	<ul> <li>Dose-related increases in nausea, vomiting, dizziness and hot flushes, but overall high-doses were well tolerated.</li> </ul>					
French 2007	Post-marketing surveillance	13,137	Patients prescribed amantadine	– 36 (0.27%) prescribed amantadine were diagnosed with corneal oedema (RR=1.7; 95% CI: 1.1, 2.8).					
Gums 2008	Retrospective review of health care claims	45,751 treated with oseltamivir and 45,751 matched untreated controls	Patients diagnosed with influenza during 5 influenza seasons in the US	<ul> <li>Statistically significant reductions in risk of pneumonia (OR= 0.89, 95% CI: 0.80, 1.00), otitis media (OR=0.84, 95% CI: 0.77, 0.91) and hospitalization (OR=0.71, 95% CI: 0.62, 0.83).</li> <li>Risk of pneumonia and otitis media were also lower in children and adolescents (≤ 17 years) prescribed oseltamivir (OR=0.4, 95% CI: 0.60, 0.91 and OR: 0.77, 95% CI: 0.69, 0.85, respectively).</li> </ul>					
Hanshaow- orakul 2009	Retrospective medical record review	2075	Thai individuals with influenza infection	<ul> <li>Treatment with oseltamivir statistically associated with survival (crude OR=0.11; 95% CI: 0.04, 0.30, controlled for age OR=0.13; 95% CI: 0.04, 0.40).</li> <li>1.5% (5/318) mortality in those oseltamivir treated, in comparison to 5% (17/131) of those untreated.</li> </ul>					
Kawai 2009	Retrospective review	*		<ul> <li>Mean duration of fever after commencing oseltamivir therapy was significantly longer in H1N1 2008-09 (49.1±30.2h) than in H3N2 (33.7±20.1h, p&lt;0.01) or H1N1 2007 08 (32.0±18.9h, p&lt;0.001).</li> <li>Mean duration of fever was longer for oseltamivir than zanamivir for 2008-09 H1N1 (<i>P</i>&lt;0.001).</li> </ul>					
Kimberlin 2009	Retrospective chart review	180	Infants treated with oseltamivir, amantadine or rimantadine	<ul> <li>Children less than one year of age treated with oseltamivir were significantly less likely to develop abnormalities in the head/eyes/ears/ nose/throat system, such as otitis media, compared to children treated with rimantadine or amantadine (1.7% versus 15.4%; p&lt;0.01).</li> </ul>					
Lee 2007	Retrospective cohort study	356	Patients hospitalized with laboratory confirmed seasonal influenza	<ul> <li>Oseltamivir initiated within 2 days of illness was associated with shorter total length of stay (Kaplan-Meier estimated median 4 versus 6 days; adjusted HR=1.54; 95% CI: 1.23, 1.92; p&lt;0.0001).</li> </ul>					

Studies Design N Popul charact				Key results					
Lee 2009	1-year prospective observational study	147	Adults hospitalized from influenza (H3N2)	<ul> <li>Antiviral treatment initiated on presentation was an independent factor affecting viral concentration.</li> <li>Treatment started on symptom days 1–4 was significantly associated with shortened viral RNA detection.</li> </ul>					
				<ul> <li>Oseltamivir started on symptom day 1–2 was also significantly associated with shortened viral RNA detection, OR=0.10 (95%CI: 0.03, 0.35; <i>p</i>&lt;0.001).</li> <li>Antiviral treatment started on symptom day 1 or days 2–3 was associated with accelerated viral concentration decrease, compared with no treatment.</li> </ul>					
Liem 2009	Retrospective review	67	Laboratory confirmed cases of H5N1 in Vietnam	<ul> <li>Risk of death was higher in patients not receiving oseltamivir treatment (<i>p</i>=0.048).</li> <li>Benefit of oseltamivir was observed even after controlling for age (OR=0.24; 95% CI: 0.065, 0.916) or neutropenia as a marker of severity (Mantel-Haenszel summary OR=0.15; 95% CI: 0.026-0.893; <i>p</i>=0.034).</li> </ul>					
Madjid 2009	Retrospective cohort study Propensity score adjusted	49,238 treated with oseltamivir 102,692 no antiviral treatment	Adults with clinical influenza diagnosis	<ul> <li>Treated with oseltamivir within 1 day before or 2 days after diagnosis.</li> <li>HR for stroke or transient ischaemic attack at 6 months was 0.717 (95% CI: 0.624, 0.823).</li> </ul>					
McGeer 2007	Prospective cohort study	327	Adult patients hospitalized for influenza	<ul> <li>- 106 of 327 (32%) prescribed antivirals.</li> <li>- Antiviral treatment was associated with significant reduction in mortality (OR=0.21; 95% CI: 0.06, 0.80).</li> </ul>					
Nordstrom 2004	Post-marketing safety study	32,459	Physician diagnosis of influenza and/or prescription for oseltamivir	<ul> <li>Adjusted rate ratio for skin reactions for oseltamivir users versus non-users was 1.05 (95% CI: 0.88, 1.24) for incident cases and 0.98 (95% CI: 0.77, 1.24) for patients with history of skin reactions.</li> <li>Oseltamivir not associated with increased risk of skin reactions.</li> </ul>					
Nordstrom 2005	Retrospective cohort study	11,632 taking oseltamivir 60,427 not taking oseltamivir	Individuals aged >1 year prescribed oseltamivir within 1 day of influenza diagnosis	<ul> <li>Pneumonia influenza-like illness: HR=0.72 (95% CI: 0.60, 0.86).</li> <li>Hospital admission with oseltamivir: HR=0.74 (95% CI: 0.61, 0.90).</li> </ul>					

Studies	Design	N	Population characteristics	Key results				
Orzeck 2007	Retrospective cohort study	2919 treated with oseltamivir 6171 not prescribed treatment	Patients with diabetes treated with oseltamivir	<ul> <li>Patients treated with oseltamivir had 17% risk reduction for respiratory illness (RR=0.83; 95% CI: 0.73, 0.93).</li> <li>A 30% risk reduction for hospitalization for any cause (RR=0.70; 95% CI: 0.52, 0.94).</li> <li>No significant differences between groups for risk of pneumonia, otitis media or hospitalizations for pneumonia.</li> </ul>				
Peters 2008	Case control study	31,674 taking oseltamivir 31,674 matched controls	Children and adults taking oseltamivir within 1 day of onset of influenza symptoms	<ul> <li>Oseltamivir reduced risk of pneumonia by 15% (RR=0.85; 95% CI: 0.73, 0.98).</li> <li>Risk reduction 20% for other respiratory illnesses (RR=0.80; 95% CI: 0.76, 0.83).</li> <li>Risk reduction 30% for otitis media and other complications (RR=0.69; 95% CI: 0.61, 0.79).</li> <li>Risk reduction 38% for overall hospital admission (RR=0.62; 95% CI: 0.52, 0.74).</li> </ul>				
Piedra 2009	Retrospective review	1634 received oseltamivir 3721 received no antiviral therapy	Paediatric patients receiving oseltamivir	- Oseltamivir was significantly associated with a reduction in respiratory illness other than pneumonia (OR=0.74; 95%CI: 0.63, 0.87), otitis media (OR=0.69; 95%CI: 0.48, 0.99), and all-cause hospitalizations (OR=0.33; 95%CI: 0.13, 0.83) within 14 and 30 days after diagnosis.				
Tanaka 2009	Literature review	90 using oseltamivir 4 using zanamivir	Pregnant women using oseltamivir or zanamivir	<ul> <li>1 malformation in 90 pregnancies with women using oseltamivir.</li> <li>For 4 women using zanamivir, one spontaneous miscarriage, one termination and 2 healthy births.</li> </ul>				

Author(s): Holger J Schunemann

Date: 2009-06-24

**Question:** Should oseltamivir be used for influenza-infected at-risk populations?

**Settings:** Outpatient

Bibliography: Blumenthals and Schulman (2007), Orzeck et al. (2007), and Gums et al. (2008).

## Table A6.2

Quality assessment						Summary of findings				a a		
Quality assessment						No of patients		Effect		port		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Oseltamivir	Control	Relative (95% CI)	Absolute	Quality	<u>E</u>
Hospitalization (follow-up mean 14 days)												
31			no serious inconsistency	no serious indirectness <sup>3</sup>	no serious imprecision	none		979/73080 (1.3%)	OR 0.73 (0.63 to 0.83) <sup>4</sup>	4 fewer per 1000 (from 2 fewer to 5 fewer)	-	CRITICAL
							625/69929 (0.9%)	10%		25 fewer per 1000 (from 16 fewer to 35 fewer)		
								20%		46 fewer per 1000 (from 28 fewer to 64 fewer)		

- 1. Although 5 observational studies were identified, only three included the outcome hospitalization.
- 2. All of these studies were case-control studies. Although we did not downgrade for selection bias, this always is a concern with this study design.
- 3. The studies were performed in patients with seasonal influenza. We did not downgrade for indirectness in relation to Influenza H1N1 infection.
- 4. We used the adjusted OR or RR from each study and calculated a pooled OR. The study by Gums et al. used propensity score matching and the unadjusted OR was used.